ImmunityBio Names Enrique Diloné As Chief Technology Officer

ImmunityBio Inc  on Thursday named Enrique Diloné to the newly created role of Chief Technology Officer.

Diloné will assume responsibility for all global manufacturing functions as the company prepares for potential FDA approval of a key bladder cancer drug.

Prior to joining ImmunityBio, Diloné served as CTO of Prothelia, a privately held biotech company developing treatments for patients with congenital muscular dystrophy.